Email Us
Call Us
AUSTIN, Texas – March 3, 2022 – Altogen Labs has expanded its in-house validated tumor model collection to 115 cell line-derived xenograft (CDX) models, 30 patient-derived xenograft (PDX) models, and over 40 syngeneic models, following the addition of seven newly validated models: A549, BT474, HUH7, MDA-MB-231, MKN-74, NCI-N87, and PC-3.
Model breadth is not a vanity metric. Preclinical oncology fails most often at the translation step, and one of the most controllable causes is testing a compound against a model that does not reflect the biology of the intended patient population. Compared with in vitro tissue culture, xenograft studies represent tumor architecture more accurately and give a better reflection of an anticancer compound’s true efficacy. A laboratory with 115 validated models can match the model to the mechanism; a laboratory with a dozen cannot.
The additions strengthen coverage across lung, breast, liver, gastric, and prostate cancer. Each model enters the collection only after tumor growth curves have been established and reproduced across multiple independent studies at the Altogen Labs facility, ensuring sponsors receive predictable kinetics and interpretable results.
Altogen Labs offers all types of preclinical research services for oncology, pharmacology, and biotechnology programs, serving the biopharmaceutical industry and academic cancer research centers. The company has been GLP-compliant and IACUC-regulated and performing both in vitro and in vivo studies since 2009, with services spanning toxicology and pharmacology studies, in vivo RNAi delivery, liposome encapsulation and tissue-targeted delivery, IC50 assays, gene function and expression analysis, cell line development, and assay development of all types.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, with a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: PR Newswire, “Over 100 In-house Validated Xenograft Models for Preclinical Testing by Altogen Labs”